Shopping Cart
Remove All
Your shopping cart is currently empty
Adintrevimab (Synonyms: ADG 20)
Catalog No. T76900 Copy Product Info
🥰Excellent
Adintrevimab is an engineered human IgG1 monoclonal antibody, which targets the conserved epitope in the receptor binding domain (RBD) of spike protein of SARS-like coronavirus, thus blocking its binding with ACE2 receptor and playing a broad-spectrum neutralization role. Adintrevimab has strong activity against many SARS-CoV-2 variants, but its neutralizing ability is obviously decreased in some Omicron subtypes.
Adintrevimab
Copy Product Info🥰Excellent
Catalog No. T76900
Synonyms ADG 20
Adintrevimab is an engineered human IgG1 monoclonal antibody, which targets the conserved epitope in the receptor binding domain (RBD) of spike protein of SARS-like coronavirus, thus blocking its binding with ACE2 receptor and playing a broad-spectrum neutralization role. Adintrevimab has strong activity against many SARS-CoV-2 variants, but its neutralizing ability is obviously decreased in some Omicron subtypes.
Adintrevimab
Cas No. 2516243-54-0
| Pack Size | Price | USA Stock | Global Stock | Quantity |
|---|---|---|---|---|
| 1 mg | $247 | 2-4 weeks | 2-4 weeks | |
| 5 mg | $647 | 2-4 weeks | 2-4 weeks | |
| 10 mg | $987 | 2-4 weeks | 2-4 weeks |
For In stock only · Estimated delivery: USA Stock (1-2 days) Global Stock (5-7 days)
Add to Cart
Add to Quotation
With extensive experience in compound synthesis, we can provide rapid custom synthesis services for this product according to your research needs.
For research use only—not for human use. No sales to individuals. Use as intended only.
Resource Download
Product Introduction
Bioactivity
Related Conjugates and Formulations
Antigen Details
Chemical Properties
Antibody Information
Storage & Solubility Information
| Description | Adintrevimab is an engineered human IgG1 monoclonal antibody, which targets the conserved epitope in the receptor binding domain (RBD) of spike protein of SARS-like coronavirus, thus blocking its binding with ACE2 receptor and playing a broad-spectrum neutralization role. Adintrevimab has strong activity against many SARS-CoV-2 variants, but its neutralizing ability is obviously decreased in some Omicron subtypes. |
| In vitro | In vitro, Adintrevimab demonstrates potent neutralization against SARS-CoV-2 variants (Alpha to Delta) by binding a conserved RBD epitope, though it shows diminished activity against Omicron BA.1 and lacks activity against BA.2-BA.5 sub-lineages [1]. |
| In vivo | In prophylactic studies using Syrian golden hamsters (5-6-week-old females) infected with SARS-CoV-2/WA1/2020, single intraperitoneal administration of Adintrevimab (9.25 to 2,000 μg, approx. 0.1 to 20 mg/kg) provided dose-dependent protection, significantly reducing lung viral load and alleviating virus-induced lung pathology [1]. |
| Synonyms | ADG 20 |
| Reactivity | Virus |
| Application | FACS Functional assay |
| Antibody Type | Monoclonal |
| Formulation | Supplied as a sterile solution in a buffered formulation system (e.g., phosphate-, citrate-, or amino acid-based). Please refer to the CoA for lot-specific composition. |
| Endotoxin | <1.0 EU/mg |
| Conjucates | Unconjugated |
| Uniprot ID | |
| Target | SARS-CoV-2 |
| Cas No. | 2516243-54-0 |
| Isotype | IgG1 |
| Storage | Store at -20°C Shipping with blue ice/Shipping at ambient temperature. |
Calculator
Preview
Related Tags: buy Adintrevimab | purchase Adintrevimab | Adintrevimab cost | order Adintrevimab | Adintrevimab in vivo | Adintrevimab in vitro
Generate Quote
Catalog No.: Cas No.:
Add
| Size | Quantity | Unit Price | Amount | Operation |
|---|
Generate Quote
- TOP
Feedback
Hello! How can I help you today? 
Copyright © 2015-2026 TargetMol Chemicals Inc. All Rights Reserved.